ACYCLOVIR TABLET

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

ACYCLOVIR

Verfügbar ab:

APOTEX INC

ATC-Code:

J05AB01

INN (Internationale Bezeichnung):

ACYCLOVIR

Dosierung:

200MG

Darreichungsform:

TABLET

Zusammensetzung:

ACYCLOVIR 200MG

Verabreichungsweg:

ORAL

Einheiten im Paket:

100

Verschreibungstyp:

Prescription

Therapiebereich:

NUCLEOSIDES AND NUCLEOTIDES

Produktbesonderheiten:

Active ingredient group (AIG) number: 0115506002; AHFS:

Berechtigungsstatus:

CANCELLED POST MARKET

Berechtigungsdatum:

2012-09-04

Fachinformation

_____________________________________________________________________________________
_ACYCLOVIR Product Monograph _
_ _
_Page 1 of 38_
PRODUCT MONOGRAPH
PR
ACYCLOVIR
ACYCLOVIR TABLETS APOTEX STANDARD
200 MG, 400 MG AND 800 MG
ANTIVIRAL AGENT
APOTEX INC.
DATE OF PREPARATION:
150 SIGNET DRIVE
April 10, 1997
TORONTO, ONTARIO
DATE OF REVISION:
M9L 1T9
February 11, 2021
Control No. 243367
_____________________________________________________________________________________
_ACYCLOVIR Product Monograph _
_Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
3
SUMMARY PRODUCT INFORMATION
..............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................................
6
DRUG
INTERACTIONS..........................................................................................................................
9
DOSAGE AND
ADMINISTRATION......................................................................................................
9
OVERDOSAGE
......................................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................
11
STORAGE AND STABILITY
...............................................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
........